Meet Exmplr AI : The next-gen clinical trial data solution. CA:0xc95E16f99267D6112eaDAA46140Bea095c8c7bA5
Joined December 2024
- Tweets 299
- Following 265
- Followers 1,873
- Likes 1,049
40 Photos and videos
Getting a lot of questions about where the project stands, so here's a real update.
First, on token price: we have no insider view on market movements and we don't comment on them. Our focus is shipping product.
On the project itself: in February 2026 we ran a serious test of Claude Opus 4.6 with plugins and MCP servers against our own SLR pipeline. Honestly, it could replicate 70–80% of what we generate. That was a wake-up call, and it pushed us in a direction we think matters more.
Our thesis has always been that research should be open and auditable, not a black box. So we've been rebuilding the engine specifically for evidence synthesis and drug discovery, with the user in control and the underlying evidence visible at every step. That's the only durable moat against a general-purpose model: vertical depth, transparency, and trust.
The version in the video below is a working build we haven't released yet. To finish it and run it at the compute scale this kind of work requires, we need to grow our resources. We're working on that.
Vertical integration is where AI in healthcare is going. We intend to be there. Thanks to everyone who's stuck with us. cleanshot.com/share/nvfQdJGK
6
1
28
3,653
Anyone can generate text. Few can produce work that regulators, scientists, and clinicians can trust.
That’s why we are focusing on:
• Evidence‑backed outputs
• Full transparency
• Auditability of every claim
• User control over reasoning and sources
Trust isn’t a feature. It’s the product. #DeSci #Virtuals $Exmplr #Healthcare #Research
3
3
350
Exmplr retweeted
Spotlight on Nicolas Altemose, assistant professor of genetics: The Altemose Lab applies new tools and technologies to explore the biology of repetitive areas of the human genome.
stanmed.stanford.edu/repetit…
ALT Nicolas Altemose, assistant professor of genetics
ALT "Some of the most important future scientific discoveries are currently hidden in unexpected places. That's why we're following our curiosity to explore the dark corners of the genome."
ALT Stanford Medicine magazine: The power of research
1
6
23
4,089
Exmplr retweeted
May 4
Top-performing Virtual projects in the last 7D
What’s your moonshot pick?👇
■ $EXMPLR @ExmplrAI
■ $EVAL @Eval_Engine
■ $VADER @Vader_AI_
■ $SHEKEL @RabbiSchlomo_Ai
■ $AIXBT @aixbt_agent
■ $SEKOIA @sekoia_virtuals
■ $CAP @Capminal
■ $FLYTE @Flyte__AI
■ $AIN @AInalyst_
■ $1000X @1000xAgent
4
4
36
2,298
4
289
Exmplr retweeted
The goal has always been to build a society of AI agents
75
46
465
21,354
Exmplr retweeted
Top 10 Trending on Virtual Protocol
$CAS
$TIBBIR
$OPG
$PHAI
$AIXBT
$EXMPLR
$SIBYL
$REPPO
$CHARLES
$INSTACLAW
@caspius_ai @ribbita2012 @OpenGradient @pharmachainAI @aixbt_agent @ExmplrAI @sibylcap @reppo @charles__AI @instaclaws
13
15
72
3,116
Innovation in action. 🚀 We’ve all seen the impact @ImmunityBio is making in healthcare—and now you can be part of it. Recruiting trials (IBRX‑042) in Austin, Houston & El Segundo.
#IBRX #EXMPLR #DeSci
Check eligibility here: exmplr.ai/sro/search
1
1
13
620
RT @ImmunityBio: Bladder cancer remains a persistent challenge in oncology, demanding meaningful innovation.
Through a multi-faceted appro…
27
Exmplr retweeted
Apr 13
This could be a MAJOR shift in cancer treatment.
Activating your body’s own “special forces” (NK & T cells) to fight cancer… and the FDA sends a warning?
@DrPatrick explains
Watch now @ youtube.com/@SeanMSpicer
16
60
299
24,247
RT @ImmunityBio: As we look ahead to the 2026 @BladderCancerUS walks, we're proud to stand alongside the bladder cancer community.
Immunit…
20
Exmplr retweeted
Feb 24
99% of x402 volume growth is coming from Virtuals Protocol, driven by agent-to-agent services on ACP.
Join the fastest-growing agent commerce network.
x402 volume is starting to pick back up to Q4/2025 level
Key driver to the increase is @virtuals_io
Majority of the demand (99% ) comes from agent-to-agent services from Virtuals ACP (e.g. data queries, swaps, workflows, and inferences)
The increase in volume came 2 weeks after the announcement of $1M monthly incentives supporting productive agents within the ACP network
First week Epoch (11 Feb - 23 Feb) saw average x402 volume doubled. Top 5 agents earned $32k - $66k in incentives (on top of their $70-$90k fee generated)
Seems like the aGDP initiatives are working
44
55
367
33,349
Exmplr retweeted
Feb 25
My husband is being featured in a documentary for groundbreaking therapies for Glioblastoma.
Unleash #ANKTIVA and NK therapies for all cancer patients! #IBRX @bullishbruk
31
87
460
7,528
🚀 The rise in FDA approvals for rare‑disease therapies is an important step but the journey from discovery to patients is still far too long.
At EXMPLR AI, we see firsthand how fragmented recruitment, slow site activation, and limited patient visibility continue to delay critical treatments for the ~30 million people living with rare conditions.
This is exactly where smarter clinical‑trial infrastructure matters:
🔹 AI‑powered patient–trial matching brings rare‑disease communities into visibility.
🔹 Automated workflows reduce burdens for sponsors, investigators, and CROs.
🔹 Real‑time analytics help teams adapt protocols faster and improve trial readiness.
🔹 Integrated communication channels keep patients, clinicians, and researchers aligned.
If regulators are opening the door to more therapies, the ecosystem must ensure those therapies reach patients faster, safer, and more equitably.
EXMPLR AI is committed to being part of that solution.
#RareDisease #OrphanDrugs #FDA #ClinicalTrials #HealthTech #AIinHealthcare #DigitalHealth #PatientCentricity #Biotech #LifeSciences #ClinicalResearch #MedTech #DrugDevelopment
Feb 24
From @WSJopinion: At the FDA, we’re approving more drugs to treat rare diseases. Our application process was designed for common ailments, but roughly 30 million Americans suffer from uncommon ones, writes @DrMakaryFDA.
on.wsj.com/46rXxXk
2
2
6
876
Exmplr retweeted
Feb 24
Unleash # ANKTIVA
Feb 23
The FDA just made one of the most significant shifts in its evidentiary standards in decades—and it feels like a lot of people have slept on the news!
The FDA will now default to ONE pivotal trial for drug approval, not two.
The science of evaluating whether a drug works has advanced enormously. Today, development programs build evidence across multiple dimensions—mechanism of action, biomarker effects, intermediate endpoints—that collectively tell a more complete story. That body of confirmatory evidence, from mechanistic data to real-world evidence, can replace a second pivotal trial.
We have historically seen more regulatory flexibility in rare diseases and oncology where need is acute. But the biggest impact we expect to see with the shift from two to one pivotal trial is likely to be in common conditions like cardiovascular and respiratory where the two pivotal trial dogma has been more entrenched. Potentially up to $350M in savings per program and years off timelines.
And this might just be the start—could continuous trial designs that collapse the rigid phase structure be the next paradigm shift in clinical development?
1
9
94
5,000
Exmplr retweeted
Feb 24
From @WSJopinion: At the FDA, we’re approving more drugs to treat rare diseases. Our application process was designed for common ailments, but roughly 30 million Americans suffer from uncommon ones, writes @DrMakaryFDA.
on.wsj.com/46rXxXk
8
12
41
27,155
RT @ImmunityBio: We're advancing global access to ANKTIVA®. A new distribution partnership with Accord Healthcare and the launch of an Iris…
88
As we move into our next chapter, we’re beginning selective conversations with strategic partners who share our vision for impact, innovation, and long‑term growth — especially across pharma, research, and related sectors. If you're in pharma and exploring forward‑thinking collaborations, let's connect.
3
222
RT @ImmunityBio: Glioblastoma presents significant scientific and clinical challenges for patients and healthcare providers. The disease's…
34